Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab PK Study in RA (Auto-Injector vs Syringe)
NCT01676701Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2012
- Primary completion
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Sep 2012; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01676701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676701.